Differences between activities of coagulation factors after one month of therapy with different direct oral anticoagulant in pulmonary embolism patients

ConclusionApixaban had a significantly higher thrombin activity, above the laboratory determined normal range, compared to patients on rivaroxaban and dabigatran. This higher thrombin activity in patients on apixaban may contribute to a better haemostatic response during the therapy or increased prothrombotic state after therapy interruption.

Source: Journal of Clinical Pharmacy and Therapeutics - November 8, 2018 Category: Drugs & Pharmacology Authors: Jelena Dzudovic, Boris Dzudovic, Vesna Subota, Marko Antunovic, Milena Stavric, Bojana Subotic, Slobodan Obradovic Tags: ORIGINAL ARTICLE Source Type: research